Tel Aviv University

Javier Ganz

Daniel Offen

Moshe Portnoy

Gerardo Zelmar Lederkremer

Hagit Eiger

Julia Leitman

Eldad Melamed

Sandu Pitaru

Compounds represented by Formula I are disclosed herein,  wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

Compounds represented by Formula I are disclosed herein, wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.

Stem cell-derived neural cells for cell therapy in neurological disorders

Growing community of inventors

Montevideo, Uruguay

Javier Ganz